XM does not provide services to residents of the United States of America.
F
F

FreseniusMedical


News

U.S. STOCKS Nasdaq, Albemarle, Haemonetics

BUZZ-U.S. STOCKS ON THE MOVE-Nasdaq, Albemarle, Haemonetics Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street fell on Tuesday, with weakness in megacap growth stocks such as Apple and Tesla weighing on the Nasdaq, while investors assessed a slew of economic data and awaited remarks from Federal Reserve Chair Jerome Powell.
A
N
S
T
A
F
U
U
D

Dialysis providers gain as investors focus on cardiac benefits after Ozempic's latest data

CORRECTED-(OFFICIAL)-UPDATE 1-Dialysis providers gain as investors focus on cardiac benefits after Ozempic's latest data Corrects paragraph 5 to say Ozempic cut the risk of death from kidney disease and major cardiac events (not just kidney disease) in diabetes patients by 24%, after company corrected its earlier information By Pratik Jain and Bhanvi Satija March 5 (Reuters) - Shares of dialysis services providers jumped between 3% and 12% on Tuesday as latest data from Novo Nordisk's NOVOb.CO h
F
N
D

Dialysis firms gain as Ozempic kidney trial data disappoints some investors

BUZZ-Dialysis firms gain as Ozempic kidney trial data disappoints some investors Updates ** Shares of dialysis firms DaVita DVA.N and U.S.-listed shares of Fresenius Medical FMS.N rise ~7 .2 % and 12 .8% respectively ** Shares of Baxter International BAX.N , which has a kidney care unit that also provides dialysis operations, gain 2 .7 % to ~$43 .6
F
N
D

Dialysis firms gain as Ozempic kidney trial data disappoints

Dialysis firms gain as Ozempic kidney trial data disappoints March 5 (Reuters) - Shares of dialysis services providers jumped in early trading on Tuesday after Novo Nordisk's NOVOb.CO popular diabetes drug Ozempic fell short of some expectations when tested on patients with chronic kidney disease. Colorado-based DaVita DVA.N rose 7.4%, while the U.S.-listed shares of rival Fresenius Medical FMS.N were up 9.5% in early trading.
F
N
D

Fresenius Medical Care Announces Sale Of Dialysis Clinics In Brazil, Colombia, Chile, Ecuador

BRIEF-Fresenius Medical Care Announces Sale Of Dialysis Clinics In Brazil, Colombia, Chile, Ecuador March 5 (Reuters) - FRESENIUS MEDICAL CARE AG FMEG.DE : FMC AG - FRESENIUS MEDICAL CARE ACHIEVES NEXT MILESTONE IN PORTFOLIO OPTIMIZATION PROGRAM, ANNOUNCING SALE OF DIALYSIS CLINICS IN BRAZIL, COLOMBIA, CHILE, ECUADOR FMC AG - DIVESTMENT OF ASSETS INCLUDES FOUR SEPARATE COUNTRY TRANSACTIONS TO DAVITA INC.
F

Dialysis provider FMC surges after Novo kidney trial

BUZZ -Dialysis provider FMC surges after Novo kidney trial ** Shares in Fresenius Medical Care FMEG.DE surge around 11% after Novo Nordisk's diabetes drug Ozempic trial showed a 24% reduction in the risk of kidney disease-related events, slightly below some investors' expectations ** "(The trial's) results weaker than expected (24% versus expected 30%).
F

Dialysis firms gain as Ozempic kidney trial data disappoints some investors

BUZZ-Dialysis firms gain as Ozempic kidney trial data disappoints some investors ** Shares of dialysis firms DaVita DVA.N and U.S.-listed shares of Fresenius Medical FMS.N rise ~8% and 12% respectively in premarket trading ** Shares of Baxter International BAX.N , which has a kidney care unit that also provides dialysis operations, gain 6.1% to ~$4
F
N
D

Novo kidney trial finds Ozempic cuts cardiac deaths in diabetics

CORRECTED-(OFFICIAL)-UPDATE 3-Novo kidney trial finds Ozempic cuts cardiac deaths in diabetics Corrects paras 1 and 5 to say that Ozempic cut the risk of death from kidney disease and major cardiac events (not just kidney disease) in diabetes patients by 24%, after company corrected its earlier information By Stine Jacobsen and Maggie Fick COPENHAGEN, March 5 (Reuters) - Novo Nordisk's widely used diabetes drug Ozempic delayed progression of chronic kidney disease in diabetes patients, a large l
F
D

Novo Nordisk Ozempic trial delays progression of chronic kidney disease

Novo Nordisk Ozempic trial delays progression of chronic kidney disease OSLO, March 5 (Reuters) - Novo Nordisk's NOVOb.CO widely used diabetes drug Ozempic delayed progression of chronic kidney disease in diabetes patients, according to a large late-stage study. "The trial achieved its primary endpoint by demonstrating a statistically significant and superior reduction in kidney disease progression, major adverse cardiovascular events (MACE) and death of 24%," it said in a statement.
F
D

European shares slip after China reforms underwhelm; tech leads losses

UPDATE 2-European shares slip after China reforms underwhelm; tech leads losses For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window Euro zone business activity closer to recovery in Feb Dialysis providers up; investors focus on cardiac benefits after Ozempic data Bayer calls off break-up to tackle challenges for up to 3 years STOXX 600 off 0.3% Updated at 1650 GMT By Khushi Singh and Ankika Biswas March 5 (Reuters) - Europe's main index dipp
A
B
L
N
T
F
E
F
U
G

EasyJet, Hikma, Kosmos Energy

EUROPE RESEARCH ROUNDUP-EasyJet, Hikma, Kosmos Energy Feb 27 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including EasyJet, Hikma and Kosmos Energy, on Tuesday. HIGHLIGHTS * EasyJet EZJ.L : JP Morgan cuts target price to 680p from 690p * Hikma HIK.L : Berenberg raises target price to 2000p from 1960p * Kosmos Energy Ltd KOS.L : Panmure Gordon raises target price to 762p from 744p * L'Oreal OREP.PA : Berenberg raises to buy from hold; rai
A
A
B
B
B
B
C
C
D
D
E
G
G
H
H
H
L
L
N
N
P
R
R
S
S
A
A
B
B
F
F
M

Gerresheimer, Repsol, SEB AB

EUROPE RESEARCH ROUNDUP-Gerresheimer, Repsol, SEB AB Feb 23 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Gerresheimer, Repsol and SEB AB on Friday. HIGHLIGHTS * Aena Sme SA AENA.MC : Citigroup raises to buy from neutral * Gerresheimer AG GXIG.DE : JP Morgan cuts target price to EUR 123.2 from EUR 126.6 * Moneysupermarket.com MONY.L : HSBC cuts target price to 295p from 305p * Repsol REP.MC : JP Morgan raises to overweight from n
A
A
B
B
B
B
B
C
C
D
D
E
E
F
G
G
H
H
I
K
N
R
S
S
A
A
A
A
F
R
S

Bechtle, Schneider Electric, Sobi

EUROPE RESEARCH ROUNDUP-Bechtle, Schneider Electric, Sobi Feb 22 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Bechtle, Schneider Electric and Sobi on Thursday. HIGHLIGHTS * Bechtle AG BC8G.DE : Berenberg raises to buy from hold; raises PT to EUR 57 from EUR 41 * Moneysupermarket.com MONY.L : Berenberg raises to buy from hold * Saab AB SAABb.ST : Citigroup cuts to neutral from buy * Schneider Electric SCHN.PA : HSBC cuts to hold
A
B
B
B
C
E
F
G
H
H
H
I
I
L
L
P
S
S
U
W
A
A
A
B
B
B
E
F
R
S
W

HSBC, healthcare stocks drag European shares lower; Fed minutes, Nvidia results eyed

UPDATE 2-HSBC, healthcare stocks drag European shares lower; Fed minutes, Nvidia results eyed For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window Glencore drops after 2023 core earnings shrink Carrefour raises dividend after 2023 profit jumps Swiss private bank EFG FY profit soars STOXX down 0.2% Updated at 1651 GMT By Shubham Batra and Khushi Singh Feb 21 (Reuters) - European shares slipped on Wednesday hurt by banking shares following a dr
C
E
G
H
N
U
F
R
E
F
U
G

Fresenius rises after Q4 beat, 'conservative' guidance

BUZZ-Fresenius rises after Q4 beat, 'conservative' guidance Updates share move, adds analyst comment ** S hares in Fresenius FREG.DE rise around 4%, reversing a fall in early trade, after the German healthcare group reported Q4 operating profit beat and announced a guidance which J.P.Morgan says can be seen as "conservative" ** Fresenius reported q
F
F
G

Fresenius slips after it forecasts lower-than-expected 2024 growth

BUZZ-Fresenius slips after it forecasts lower-than-expected 2024 growth ** German healthcare group Fresenius' FREG.DE stock is down 1.7% in early trade, as it forecast lower-than-expected revenue and earnings growth this year ** Fresenius sees organic revenue growth of between 3% and 6% and EBIT growth of between 4% and 8% at constant currency ** A
F
F
G

Healthcare group Fresenius tops Q4 profit forecast, shares rise

UPDATE 2-Healthcare group Fresenius tops Q4 profit forecast, shares rise Recasts with share move, savings target By Tristan Veyet Feb 21 (Reuters) - German healthcare firm Fresenius FREG.DE beat expectations with a 13% jump in fourth-quarter operating earnings on Wednesday after it exceeded its costs savings target for 2023. CEO Michael Sen, who took the helm a year ago, has been restructuring the group to cut costs and debt after it was hit by a decline in earnings at its former dialysis unit F
F
F
G

Healthcare group Fresenius tops Q4 operating profit expectations

Healthcare group Fresenius tops Q4 operating profit expectations Feb 21 (Reuters) - Fresenius FREG.DE reported a bigger-than-expected 13% jump in fourth-quarter operating profit on Wednesday, citing good earnings development across its businesses and progress in the operational turnaround at its hospital project development unit Vamed. The diversified healthcare group reported quarterly earnings before interests and taxes, and before special items, of 634 million euros ($685 million), 7% above a
F
F

European shares slip on miners, energy drag; France's Air Liquide hits record high

UPDATE 2-European shares slip on miners, energy drag; France's Air Liquide hits record high For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window Negotiated EZ wage growth slows in Q4 from record high Air Liquide hikes 2025 margin target after full-year beat Barclays focuses on Britain, cost cuts, buybacks FMC slides as analysts focus on weak patient volumes outlook Updated at 1650 GMT By Khushi Singh and Ankika Biswas Feb 20 (Reuters) - Europ
B
B
H
O
R
T
A
F
E
F
U
G

European futures edge lower, Barclays unveils overhaul

LIVE MARKETS-European futures edge lower, Barclays unveils overhaul Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com EUROPEAN FUTURES EDGE LOWER, BARCLAYS UNVEILS OVERHAUL European shares were set to open lower on Tuesday, after a cut in China's mortgage rate failed to impress markets, which were awaiting for Nvidia numbers on Wednesday to gauge the potential for an AI-driven glob
B
N
O
T
A
F
U



Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.